Evidence that Treatment with Risedronate in Women with Postmenopausal Osteoporosis Affects Bone Mineralization and Bone Volume

[1]  S M Jorgensen,et al.  Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. , 2006, Bone.

[2]  P. Fratzl,et al.  Effects of 3‐ and 5‐Year Treatment With Risedronate on Bone Mineralization Density Distribution in Triple Biopsies of the Iliac Crest in Postmenopausal Women , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  P. Geusens,et al.  Relationship Between Changes in BMD and Nonvertebral Fracture Incidence Associated With Risedronate: Reduction in Risk of Nonvertebral Fracture Is Not Related to Change in BMD , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  G. Dalsky,et al.  Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. , 2005, Archives of internal medicine.

[5]  M. Hochberg,et al.  How useful are measures of BMD and bone turnover?* , 2005, Current medical research and opinion.

[6]  S. Epstein.  The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. , 2005, Mayo Clinic proceedings.

[7]  Richard Eastell,et al.  Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. , 2004, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[8]  D. Bauer,et al.  Change in Bone Turnover and Hip, Non‐Spine, and Vertebral Fracture in Alendronate‐Treated Women: The Fracture Intervention Trial , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  Himadri S. Gupta,et al.  Structure and mechanical quality of the collagen–mineral nano-composite in bone , 2004 .

[10]  Ego Seeman,et al.  Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. , 2004, Bone.

[11]  L. Qin,et al.  Parathyroid hormone: a double-edged sword for bone metabolism , 2004, Trends in Endocrinology & Metabolism.

[12]  M. McClung.  Use of highly potent bisphosphonates in the treatment of osteoporosis , 2003, Current osteoporosis reports.

[13]  Mary L Bouxsein,et al.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.

[14]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  Huajian Gao,et al.  Materials become insensitive to flaws at nanoscale: Lessons from nature , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Fratzl,et al.  Constant mineralization density distribution in cancellous human bone. , 2003, Bone.

[17]  P. Fratzl,et al.  Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. , 2003, The Journal of clinical endocrinology and metabolism.

[18]  P. Fratzl,et al.  Characteristics of mineral particles in the human bone/cartilage interface. , 2003, Journal of structural biology.

[19]  F Melsen,et al.  Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. , 2002, Bone.

[20]  P. Meunier,et al.  The Degree of Mineralization of Bone Tissue Measured by Computerized Quantitative Contact Microradiography , 2002, Calcified Tissue International.

[21]  P. Fratzl,et al.  Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. , 2001, Bone.

[22]  P. Fratzl,et al.  Mineralized collagen fibrils: a mechanical model with a staggered arrangement of mineral particles. , 2000, Biophysical journal.

[23]  J. Reginster,et al.  Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. , 2000, The Journal of clinical endocrinology and metabolism.

[24]  J. Kanis.  An update on the diagnosis of osteoporosis , 2000, Current rheumatology reports.

[25]  J. Currey.  The design of mineralised hard tissues for their mechanical functions. , 1999, The Journal of experimental biology.

[26]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[27]  P. Fratzl,et al.  Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies. , 1998, Bone.

[28]  P. Fratzl,et al.  Mineralization of cancellous bone after alendronate and sodium fluoride treatment: a quantitative backscattered electron imaging study on minipig ribs. , 1997, Bone.

[29]  P. Miller,et al.  Prediction of fracture risk. I: Bone density. , 1996, The American journal of the medical sciences.

[30]  H. Plenk,et al.  A new scanning electron microscopy approach to the quantification of bone mineral distribution: backscattered electron image grey-levels correlated to calcium K alpha-line intensities. , 1995, Scanning microscopy.

[31]  M. Wolcott.  Cellular solids: Structure and properties , 1990 .

[32]  C. Cann,et al.  Quantitative CT for determination of bone mineral density: a review. , 1988, Radiology.

[33]  W. Greiner.  Highlights of the conference , 1983 .

[34]  J. Whitfield,et al.  Parathyroid Hormone, Its Fragments and Their Analogs for the Treatment of Osteoporosis , 2002, Treatments in endocrinology.

[35]  C. Christiansen,et al.  Six and Twelve Month Changes in Bone Turnover are Related to Reduction in Vertebral Fracture Risk During 3 Years of Raloxifene Treatment in Postmenopausal Osteoporosis , 2001, Osteoporosis International.

[36]  NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. , 2001, Southern medical journal.

[37]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[38]  D. Dempster,et al.  Trabecular architecture in iliac crest bone biopsies: infra-individual variability in structural parameters and changes with age. , 1988, Bone.

[39]  M. Ashby,et al.  Cellular solids: Structure & properties , 1988 .

[40]  A. Boyde,et al.  Scanning electron microscopy in bone pathology: review of methods, potential and applications. , 1986, Scanning electron microscopy.